

BIOCHEMISTRY

Dissecting structure-function of 3-O-sulfated heparin and engineered heparan sulfates

Richard Karlsson^{1†}, Pradeep Chopra^{2†}, Apoorva Joshi^{2,3}, Zhang Yang^{1,4}, Sergey Y. Vakhrushev¹, Thomas Mandel Clausen⁵, Chelsea D. Painter⁵, Gergo P. Szekeres^{6,7}, Yen-Hsi Chen^{1,4}, Daniel R. Sandoval⁵, Lars Hansen¹, Jeffrey D. Esko^{5,8}, Kevin Pagel^{6,7}, Douglas P. Dyer⁹, Jeremy E. Turnbull^{1,10}, Henrik Clausen^{1*}, Geert-Jan Boons^{2,3,11*}, Rebecca L. Miller^{1*}

Heparan sulfate (HS) polysaccharides are master regulators of diverse biological processes via sulfated motifs that can recruit specific proteins. 3-O-sulfation of HS/heparin is crucial for anticoagulant activity, but despite emerging evidence for roles in many other functions, a lack of tools for deciphering structure-function relationships has hampered advances. Here, we describe an approach integrating synthesis of 3-O-sulfated standards, comprehensive HS disaccharide profiling, and cell engineering to address this deficiency. Its application revealed previously unseen differences in 3-O-sulfated profiles of clinical heparins and 3-O-sulfotransferase (HS3ST)-specific variations in cell surface HS profiles. The latter correlated with functional differences in anticoagulant activity and binding to platelet factor 4 (PF4), which underlies heparin-induced thrombocytopenia, a known side effect of heparin. Unexpectedly, cells expressing the HS3ST4 isoenzyme generated HS with potent anticoagulant activity but weak PF4 binding. The data provide new insights into 3-O-sulfate structure-function and demonstrate proof of concept for tailored cell-based synthesis of next-generation heparins.

INTRODUCTION

The heparan sulfate (HS) family of polysaccharides found throughout metazoan lifeforms comprises the most anionic polysaccharides in nature ranging from 20 to 200 monosaccharide units in length, and HS is ubiquitously expressed on cell surfaces and in the extracellular matrix of mammals. HS is essential for life in all mammalian species and modulates numerous biological activities involving growth and development, inflammation and immune system regulation, angiogenesis and metabolism, as well as disease pathologies of cancer, infection, and neurodegenerative disorders (1, 2). The degree and patterns of their sulfation represent huge diversity for informational cues to direct and tightly regulate biological functions. They achieve this through selective interactions with protein partners via divergent sulfated binding motifs that bind to cognate protein-binding sites. HS is produced by a complex biosynthetic machinery that initially creates a repeating disaccharide unit of uronic acid (UA)

and *N*-acetylglucosamine (GlcNAc), where the UA is either iduronic acid (IdoA) or glucuronic acid (GlcA). The glucosamines can be modified with an *N*-sulfate (NS) or remain as an *N*-acetyl (NAc) moiety [via action of *N*-deacetylase/*N*-sulfotransferases 1 to 4 (NDST1 to NDST4)]. UAs can subsequently be modified with an *O*-sulfate at the carbon-2 position by 2-*O*-sulfotransferase (HS2ST1). Further *O*-sulfates can be added to glucosamine residues at the carbon-6 position [via 6-*O*-sulfotransferases 1 to 3 (HS6ST1 to HS6ST3)] and more rarely at the carbon-3 position [via 3-*O*-sulfotransferases 1 to 6 (HS3ST1 to HS3ST6)]. Divergent patterns of sulfation created by the orchestration of these enzyme families are the key hallmarks of functionally specific protein-binding sites in HS. Deciphering the details of these sulfation patterns, including the apparently less common 3-*O*-sulfate modification, remains a major hurdle.

Heparin, a member of the HS family, is a widely used anticoagulant and is the world's most sold biopharmaceutical by weight, yet it remains a poorly characterized heterogeneous animal-sourced product (3, 4). Most unfractionated heparin (UFH) is purified from porcine intestinal mucosa, with low-molecular weight heparins (LMWHs) being fractionated from UFH (5, 6). In addition, the supply and quality of heparins are causes for concern due to infection outbreaks in animal stocks, such as the ongoing swine flu in China, and the contamination of crude heparin with oversulfated glycosaminoglycans (GAGs) in 2007 that resulted in many deaths (7, 8).

The mechanism of heparin's anticoagulant activity involves predominantly heparin binding and activation of antithrombin III (ATIII), which is then able to complex and inactivate thrombin, factor Xa (FXa), and other proteases (9). Heparin binds to ATIII through a specific pentasaccharide sequence, GlcNS6S-GlcA-GlcNS3S6S-IdoA2S-GlcNS6S, whereas the interaction of ATIII and thrombin requires heparin chains of at least 18 monosaccharide units in length (10). In contrast, FXa activity via ATIII activation requires only the pentasaccharide sequence, and a synthetic heparin mimetic (fondaparinux) has been created on the basis of this structure (11). Removal of the 3-*O*-sulfate group on the 3-*O*-sulfated glucosamine

¹Copenhagen Center for Glycomics, Department of Cellular and Molecular Medicine, Faculty of Health Sciences, University of Copenhagen, Blegdamsvej 3, DK-2200 Copenhagen N, Denmark. ²Complex Carbohydrate Research Center, University of Georgia, Athens, GA 30602, USA. ³Department of Chemistry, University of Georgia, Athens, GA 30602, USA. ⁴GlycoDisplay ApS, Blegdamsvej 3, DK-2200 Copenhagen N, Denmark. ⁵Department of Cellular and Molecular Medicine, University of California, San Diego, La Jolla, CA 92093, USA. ⁶Freie Universitaet Berlin, Institute of Chemistry and Biochemistry, Arnimallee 22, 14195 Berlin, Germany. ⁷Fritz Haber Institute of the Max Planck Society, Faradayweg 4-6, 14195 Berlin, Germany. ⁸Glycobiology Research and Training Center, University of California, San Diego, La Jolla, CA 92093, USA. ⁹Wellcome Centre for Cell-Matrix Research, Geoffrey Jefferson Brain Research Centre, Lydia Becker Institute of Immunology and Inflammation, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK. ¹⁰Centre for Glycobiology, Department of Biochemistry and Systems Biology, Institute of Systems, Molecular & Integrative Biology, University of Liverpool, Liverpool, UK. ¹¹Department of Chemical Biology and Drug Discovery, Utrecht Institute for Pharmaceutical Science, and Bijvoet Center for Biomolecular Research, Utrecht University, Universiteitsweg 99, 3584 CG Utrecht, Netherlands.

*Corresponding author. Email: rmillers@sund.ku.dk (R.L.M.); giboons@ccrc.uga.edu (G.-J.B.); hclau@sund.ku.dk (H.C.)

†These authors contributed equally to this work.

(GlcNS3S6S) within the pentasaccharide sequence was shown to result in limited ATIII activity (12), demonstrating the essential requirement for 3-O-sulfation for potent anticoagulant activity.

Major complications of heparin and LMWH in clinical use include both bleeding and thrombosis. The structural heterogeneity of heparins provides the avidity to complex with large numbers of proteins including plasma proteins, which can lead to adverse consequences of unpredictable anticoagulation and also life-threatening heparin-induced thrombocytopenia (HIT) (13). HIT can be non-immune or immune-mediated, both resulting in decreased platelet counts. Platelets produce a protein called platelet factor 4 (PF4; also called CXCL4), which is capable of forming large heparin-PF4 complexes; in immune HIT, antibodies to these complexes are induced and platelets are activated, resulting in the formation of blood clots and low platelet levels (13, 14). Heparin has the highest incidence of HIT at around 5% of patients, whereas LMWH has an incidence of around 1% (15). Heparin/LMWH binding to PF4 has previously been demonstrated to require N-sulfation of the glucosamine (GlcNS) and 2-O-sulfation of the UA (UA2S) (16). This raises the possibility of better targeting of heparin therapeutics with reduced side effects by tailored generation of optimized structures.

Exploiting the evident biomedical potential of heparin and HS requires systematic structure–function relationship studies, which in turn requires detailed structural elucidation. Current methods for disaccharide analysis of HS, most commonly high-performance liquid chromatography (HPLC)–based methods, do not permit complete identification of disaccharide units containing 3-O-sulfation of the glucosamine, primarily due to lack of standards. Although a few isolated 3-O-sulfated disaccharides have been studied (17, 18), many are not available for disaccharide analyses. Digestion of heparins commonly results in digestion-resistant 3-O-sulfated tetrasaccharide structures (19), adding to the difficulties of retrieving the 3-O-sulfated disaccharide standards. The 3-O-sulfation step is catalyzed by seven isoenzymes, the expression of which is spatiotemporally regulated in a broad range of tissues (20–22). HS3ST1/5 are considered to be the main isoenzymes involved in 3-O-sulfation of the anticoagulant drug heparin (produced in mast cells and from which UFH is derived) (23, 24), and a number of isozymes have been implicated in herpes simplex virus entry to cells (24, 25). The HS3STs remain incompletely characterized, despite the fact that the 3-O-sulfate modification is increasingly being linked to much broader biological functions, including tissue formation, brain symmetry, and neuronal growth (2, 20, 22). Silencing of HS3ST expression is observed in cancers (26, 27), and 3-O-sulfation enhances tau phosphorylation and plaque formation in Alzheimer's disease (28). Despite increasing insights into biological functions, the structural features of HS that drive these biological activities, and crucially the role of 3-O-sulfate groups, remain largely unknown (29) due to the limitations of analytical methods. This represents a major gap in knowledge, which must be closed in order to exploit HS/heparin in new therapeutic applications.

The numerous roles that GAGs play in protein interactions have led to initial efforts to systematically engineer GAG biosynthetic pathways using a combinatorial genetic approach for generating large libraries of individual cells that display different repertoires of HS, chondroitin sulfate (CS), and dermatan sulfate structures (30, 31). The genetic engineering approach has enabled the dissection of protein-binding features, as well as the expression of a large library of homogeneous GAGs with differences in sulfation patterns that can be expressed with and without a proteoglycan core. These can

be used for studies on extracellular matrices, mechanical properties, hydrogels, technology platforms, and biotherapeutics. Chemical and chemoenzymatic synthesis of oligosaccharide structures linked to array platforms has also been initiated to elucidate specific binding motifs (17, 32), platforms for GAG sequencing methods (33–38), and development of technology to synthesize fondaparinux in fewer steps (39). These approaches have the potential to contribute to dissecting the binding specificities of HS for a range of HS-binding proteins (30–34), but 3-O-sulfation has not been tackled in a systematic manner to date.

Here, we demonstrate an integrated strategy for dissecting the roles of 3-O-sulfation in HS and heparin by combining an optimized HPLC method that enables comprehensive disaccharide analysis of HS and heparin/LMWH with genetic engineering in cells lacking expression of HS3STs (Fig. 1, A to D). The comprehensive HPLC method was validated with a complete set of chemoenzymatically synthesized 3-O-sulfated disaccharide standards (Fig. 1, A and B) and applied to demonstrate unique 3-O-sulfate profiles of clinical heparin/LMWHs. We further exploited the strategy to explore the functional properties of the HS3ST isoenzyme family by individual targeted knockin (KI) of all seven human HS3STs in Chinese hamster ovary (CHO) cells (Fig. 1D). The resulting HS species displayed divergent 3-O-sulfation and disaccharide compositions, and also modified functional properties (Fig. 1C). We demonstrate that CHO cells expressing HS3ST4 generated HS chains with potent anticoagulant activity similar to some LMWHs, yet very weak ability to bind PF4, indicating potential for reduced HIT. These results provide proof of concept for cell-based biosynthesis of an anticoagulant HS with improved therapeutic properties (Fig. 1E). Furthermore, the integrated strategy provides a new basis for dissecting the distinct sulfated motifs that drive the many biological functions of HS.

RESULTS

Production of 3-O-sulfated disaccharide standards

A widely used approach for evaluating structural composition of heparin/HS is profiling of disaccharide building blocks, typically by digestion with a mixture of heparin lyases followed by HPLC-based separation methods with ultraviolet, fluorescence, or mass spectrometry (MS) detection. Yet, no method to date is inclusive of all 3-O-sulfated disaccharides due to the lack of suitable standards. We set out to resolve this longstanding issue by producing 3-O-sulfated tetrasaccharides having different patterns of N-, 2-O-, and 6-O-sulfations (Fig. 2A, fig. S1, table S1, and supplementary experimental methods), which, after exposure to heparinases, were expected to provide the required disaccharide standards 1 to 8 having a 3-O-sulfate moiety. The strategy entailed the chemical synthesis of tetrasaccharides that are modified by protecting groups (9 to 16) that, at a late stage of synthesis, can selectively be removed to reveal alcohols that can then be sulfated. This strategy overcomes the incompatibility of chemical oligosaccharides assembly in the presence of sulfates. Thus, disaccharide donor 21 and disaccharide acceptors 17 to 20 were coupled to give four tetrasaccharides that are modified by different patterns of levulinoyl esters and a naphthylmethyl ether. These protecting groups could selectively be removed by treatment with hydrazine acetate and 2,3-dichloro-5,6-dicyano-1,4-benzoquinone, respectively. The resulting alcohols were sulfated by sulfur trioxide-triethylamine complexes ($\text{SO}_3\cdot\text{NEt}_3$). Next, the esters were saponified and the azido moieties were reduced to amines, which were either




Fig. 1. Strategy for dissection of 3-O-sulfation structure-function and engineering of a cell-based HS anticoagulant. (A) Chemical synthesis is used to generate 3-O-sulfated tetrasaccharides, which are subsequently digested to the 3-O-sulfated disaccharide standards required for complete analysis of HS and heparin/LMWHs. (B) A comprehensive HPLC method is developed for the analysis of HS and heparin/LMWH disaccharide composition including 3-O-sulfation. (C) To generate a cell-based anticoagulant, functional assays for anticoagulant activity are used for comparing HS from genetically engineered cells with clinical heparin/LMWHs. A major side effect of heparin is HIT due to PF4 binding to heparin chains; therefore, PF4 binding of HS/heparin/LMWHs is measured to identify low-binding variants that would not generate this side effect. (D) CHO cells produce CS/dermatan sulfate (DS) GAGs as well as HS, which necessitates laborious and problematic purification for isolation of HS chains. To avoid this, CRISPR-Cas9 can be used to KO genes to ablate CS/DS biosynthesis. Targeted stable KI of genes can be achieved using ZFNs, producing CHO cell lines individually expressing the seven HS3STs, resulting in a cell-based HS3ST library. (E) Heparin/LMWHs are widely used anticoagulant drugs, yet are complex, heterogeneous, and poorly characterized animal products derived predominantly from porcine intestinal mucosa. Cell-based production could offer reduced complexity, and genetic engineering of the heparin/HS biosynthetic pathway in cells can generate a more homogeneous population of HS/heparin chains with desired properties.

N-sulfated or N-acetylated and then subjected to hydrogenation to provide the targeted tetrasaccharides 9 to 16.

These tetrasaccharides were subjected to heparinase digestion to provide the eight 3-O-sulfated disaccharides (1 to 8) required for compositional analysis of heparin/HS chains. A challenge, however,

was that 3-O-sulfation can cause resistance to heparinase digestion, resulting in undigested tetrasaccharide products from HS/heparin substrates (19). To address this issue, the chemically synthesized tetrasaccharide GlcA-GlcNS6S-GlcA-GlcNS6S3S (G0S6-G0S9) (10, Fig. 2A), a known resistant structure, was used to develop a protocol




Fig. 2. Synthetic route to access 3-O-sulfated HS disaccharide standards underpinning a comprehensive HPLC-based disaccharide composition method for heparin/HS. (A) A modular synthetic approach from common disaccharide building blocks was used to generate tetramers, followed by a sequence of O- and N-sulfation and global deprotection to yield sulfated tetrasaccharides, which, upon lyase digestion, afforded eight 3-O-sulfated authentic disaccharide standards (1 to 8 on the right of the figure). Supplementary experimental methods provide complete details of synthesis and analysis. (B) Upper chromatogram shows C18 HPLC separation of the 12 commonly used commercially available disaccharide standards, while lower chromatogram shows separation of an expanded panel of disaccharide standards including the eight 3-O-sulfated disaccharides synthesized as above in (A). AMAC-labeled disaccharides (20 pmol) were separated in each run using a gradient elution program of 0 to 18 min (18.5% buffer B), 18 to 30 min (18.5 to 19% B), 30 to 57 min (19 to 27% B), and 57 to 70 min (27 to 51% B) at 0.2 ml/min at 30°C and fluorescence detection at 525 nm. Dotted lines indicate elution times for disaccharide standards. Peaks at ~22, ~29, and ~32 min are derived from the Δ UA-GlcNS6S (D0S6), Δ UA2S-GlcNS (D2S0), and Δ UA2S-GlcNAc3S6S (D2A9) disaccharides, respectively.

that permitted heparin lyase conversion into the corresponding disaccharide products (fig. S2). Because heparinases are known to be unstable enzymes prone to loss of activity after freeze-thaw cycles (40), freshly resuspended lyophilized heparinases were used. Enzymatic digestion was carried out under optimized buffer conditions for heparinase activity with prevention of peeling reaction (41) and the stepwise addition of heparinase I (2 hours), heparinase III (2 hours),

and heparinase II (2 hours), and complete digestion of tetrasaccharide 10 was accomplished. This protocol was used to digest all eight synthesized tetrasaccharides (fig. S3 and tables S1 and S2), generating four N-acetylated disaccharides [1—(Δ UA-GlcNAc3S6S (D0A9); 3— Δ UA-GlcNAc3S (D0A3); 5— Δ UA2S-GlcNAc3S6S (D2A9); 7— Δ UA2S-GlcNAc3S (D2A3)] and four N-sulfated disaccharides [2— Δ UA-GlcNS3S6S (D0S9); 4— Δ UA-GlcNS3S (D0S3);

6- Δ UA2S-GlcNS3S6S (D2S9); 8- Δ UA2S-GlcNS3S (D2S3)] (Fig. 2A). Note that digestion by heparinases (lyase enzymes) introduces a double bond between carbon atoms 4 and 5 on the GlcA/IdoA residues, resulting in loss of distinction between these Δ UA isomers, as is the case with standard heparinase digestion of heparin/HS for compositional analysis. To improve sensitivity of detection and facilitate isolation of the disaccharide standards, the tetrasaccharides and the digestion products were derivatized with fluorescent 2-aminoacridone (AMAC) via reductive amination. This was followed by purification by reversed-phase HPLC using C18, resulting in eight 3-O-sulfated disaccharide standards, the structures of which were verified by MS and MS/MS (figs. S4 and S5).

HPLC method for comprehensive HS disaccharide analysis

Next, we developed an HPLC protocol that can separate the 12 conventional and the 8 new 3-O-sulfated disaccharide standards expected to cover the complete range of disaccharides found in heparin/HS (Fig. 2B and table S3). C18 chromatography using 150 mM ammonium acetate with 46 mM dibutylamine (pH 5.6) as buffer A and 120 mM ammonium acetate with 36.8 mM dibutylamine and 20% acetonitrile as buffer B provided baseline separation of most standards. Partial overlaps of four disaccharide pairs were noted [Δ UA2S-GlcNS6S (D2S6)/ Δ UA2S-GlcNS3S (D2S3), Δ UA-GlcNAc3S6S (D0A9)/ Δ UA-GlcNS (D0S0), Δ UA2S-GlcNH₂ (D2H0)/ Δ UA2S-GlcNAc6S (D2A6), and Δ UA-GlcNH₂ (D0H0)/ Δ UA-GlcNAc6S (D0A6)], but quantitation could still be achieved.

Compositional HPLC analysis of clinical heparins and LMWHs

To verify that the optimized heparinase digestion protocol allows complete depolymerization of full-length 3-O-sulfate containing heparin as observed for the chemically synthesized tetrasaccharides (figs. S2 and S3), a dose-dependent heparinase digestion of porcine mucosal heparin (PMH) was evaluated using size exclusion chromatography (SEC) and C18 ion-pairing chromatography (Fig. 3, A and B, and figs. S6 and S7). Complete digestion without trace of resistant tetrasaccharides was achievable at 500 mU of each heparinase per milligram of PMH.

The optimized digestion protocol and HPLC method were used to analyze clinical-grade heparins (UFHs/LMWHs) (table S4). This is important because of their known heterogeneity, relatively incomplete characterization, and the pressing need for better quality control. Notably, distinct disaccharide profiles for each were observed (Fig. 3, C and D, and fig. S8). The UFHs [PMH and bovine mucosal heparin (BMH)] contain four 3-O-sulfated structures [Δ UA2S-GlcNS3S6S (D2S9)/ Δ UA-GlcNS3S6S (D0S9)/ Δ UA2S-GlcNS3S (D2S3)/ Δ UA-GlcNS3S (D0S3)]. The main disaccharide for both was Δ UA2S-GlcNS6S (D2S6), while BMH was particularly rich in Δ UA2S-GlcNS (D2S0). We tested four PMH-derived LMWHs including enoxaparin (fractionated after benzylation and alkaline hydrolysis), tinzaparin (produced by enzymatic digestion), and dalteparin and reviparin (produced by partial nitrous acid depolymerization) (42). Enoxaparin and tinzaparin had disaccharide profiles similar to PMH, with the main difference being tinzaparin having lower amounts of Δ UA2S-GlcNS3S (D2S3) (Fig. 3, C and D, and fig. S8). Dalteparin and reviparin both demonstrated larger peaks for the Δ UA-GlcNS3S6S (D0S9) disaccharide. BMH was found to contain slightly more Δ UA2S-GlcNS3S6S (D2S9) than the other heparins, indicating that this structure may not be as prevalent in porcine-derived heparins. None of the 3-O-sulfated N-acetylated structures were observed.

Next, we analyzed the anticoagulant activity of the clinical heparins by the commonly used anti-FXa assay, in which the ability to induce a conformational change in ATIII is measured via inhibition of cleavage of a FXa substrate (fig. S9A). As expected, the UFHs demonstrated a higher level of anticoagulant activity than the LMWHs. Next, we tested the propensity of the panel of heparins to bind the HIT-inducing agent PF4 (fig. S9B). LMWHs have reduced HIT side effects compared to UFHs due to their shorter chain lengths (43). All UFHs and LMWHs demonstrated PF4 binding, with UFHs demonstrating the strongest binding. An exception was the LMWH tinzaparin, which showed binding similar to BMH.

HS3ST-dependent alterations in HS profiles

It is very noteworthy that the apparently rare but functionally important step of the addition of 3-O-sulfate group to a HS chain is catalyzed by seven isoenzymes. HS3ST2/4/3A/3B/6 share a high sequence similarity in humans with ~70% sequence overlap, where HS3ST3A and HS3ST3B share identical catalytic domains, and HS3ST1 and HS3ST5 are less similar to the other HS3STs (fig. S10A) (20–22, 24, 44). As a further step toward systematic unraveling of the importance of 3-O-sulfation for the structure and bioactivity of HS, we used a genetic engineering approach to individually KI all seven human HS3STs into CHO cells (Fig. 4A and tables S5 to S11). CHO cells were selected as they are devoid of background HS3ST expression (45, 46). Furthermore, CHO cells express both HS and CS, and to avoid the presence of CS as a contaminating GAG, we used a genetically engineered cell line with knockout (KO) of *CSGalNacT1/CSGalNacT2/Chsy1* (designated as CHO KO CS), where KI of the seven human HS3STs was performed by site-directed zinc finger nuclease (ZFN) gene KI (Fig. 4A). Expression of the HS3ST enzymes was confirmed by immunocytochemistry and sodium dodecyl sulphate–polyacrylamide gel electrophoresis (SDS-PAGE) Western blot analysis (figs. S10, B and C, and S11). HS3ST1 lacks an apparent transmembrane domain and was predominantly detected as a secreted protein in the culture medium (figs. S10 and S11). This may question the role of this isoenzyme in intracellular sulfation of HS. It is presently unclear what the biological roles of secreted sulfotransferases and glycosyltransferases are given that these enzymes require high concentrations of donor substrates provided in the Golgi. Expression of secreted glycosyltransferases has, however, demonstrated variable efficiency in intracellular glycosylation (47, 48). It should be noted that replacing the signal peptide in HS3ST1 with a Golgi targeting transmembrane domain results in increased FXa activity of cellular HS (44), indicating that HS3ST1 at least primarily functions intracellularly. HS3ST2/6 was observed only in the cell lysate, and HS3ST5/4/3A/3B was observed in both lysate and culture medium, potentially indicating extracellular activities of these enzymes. The presence of sulfotransferases in the medium may be due to proteolytic cleavage of the transmembrane domains, which has previously been shown to result in secretion of HS3STs, NDSTs, and HS6STs (49, 50).

Our genetically engineered HS3ST-expressing CHO cells and the newly developed HS compositional analysis approach were combined to study the properties of the seven HS3STs by analyzing the HS produced in these cells at the disaccharide level (Fig. 4, B and C, and fig. S12). HPLC disaccharide analysis revealed distinct differences for most KI clones compared to the parent CHO cell. HS3ST1 primarily introduced Δ UA-GlcNS3S (D0S3), suggesting that Δ UA-GlcNS (D0S0) is the preferred substrate. In contrast, the related




Fig. 3. Comprehensive disaccharide analysis of clinical heparins and LMWHs. (A) Selective clinical UFHs and LMWHs were digested sequentially using heparinases I, III, and II, resulting in disaccharide products. (B) SEC of heparinase-digested products of PMH using heparinases at PMH concentrations of 50 and 500 mU/mg (elution was monitored at 232 nm). Chromatograms for the complete set of heparinase concentrations used for the experiment can be found in figs. S6 and S7. (C) Fluorescence C18 HPLC disaccharide analysis of PMH and reviparin (an LMWH). Disaccharide products of sequential heparinase digestion were labeled with AMAC before analysis and were compared with 20 pmol standards. Dotted lines indicate elution times for authentic disaccharide standards (red dotted lines, 3-O-sulfated disaccharides; truncated lines, disaccharides not found in the samples). The Δ UA2S-GlcNS3S (D2S3) and Δ UA-GlcNS3S (D0S3) disaccharides partially coelute with the highly abundant Δ UA2S-GlcNS6S (D2S6), reducing certainty of quantification for these disaccharides. Stars in the chromatograms indicate peaks that stem from the heparinases. Chromatograms for all analyzed heparins/LMWHs are provided in fig. S8. (D) Heat map of compositional differences in 3-O-sulfated disaccharide products from digested heparin/LMWHs compared to PMH. The heat map was constructed by quantifying the molar amounts of each disaccharide in a sample as percent of the total disaccharides and comparing this to the amounts found in the sample from PMH. The color coding illustrates increase/decrease observed in percentile ranges as indicated: +++, >5% increase; ++, 2.5 to 5% increase; +, 1 to 2.5% increase; -, 1 to 2.5% decrease; --, 2.5 to 5% decrease; ---, >5% decrease.

HS3ST5 (51, 52) mainly introduced Δ UA2S-GlcNS3S (D2S3) and Δ UA2S-GlcNS3S6S (D2S9). HS3ST2 displayed a preference for 2-O-sulfated epitopes as Δ UA2S-GlcNS3S (D2S3) was the main 3-O-sulfated disaccharide; however, note that HS3ST2 generated minimal Δ UA-GlcNS3S (D0S3) units. HS3ST4 displayed high levels of all four 3-O- and N-sulfated disaccharides, indicating that the enzyme is active on a wider range of substrates. As expected, HS3ST3A/3B showed similar disaccharide profiles, and in this case, Δ UA2S-GlcNS3S (D2S3) and Δ UA-GlcNS3S (D0S3) were the predominant 3-O-sulfated disaccharides. CHO cell HS from HS3ST6 showed a disaccharide profile very similar to the parental clone with minute levels of 3-O-sulfation detected. Although CHO cells are believed to lack expression of HS3STs, we unexpectedly noticed a peak corresponding to Δ UA-GlcNS3S6S (D0S9) in the digested HS from the parental CHO cell. To investigate this peak, we performed disaccharide profiling of a CHO cell with KO of all 6-O-sulfotransferases (CHO KO *Hs6st1/2/3*), which should thus be incapable of producing Δ UA-GlcNS3S6S (D0S9) (fig. S13). Because a peak corresponding to Δ UA-GlcNS3S6S (D0S9) was not observed for CHO KO *Hs6st1/2/3*,

we suggest that, in CHO KO CS, the Δ UA-GlcNS3S6S (D0S9) disaccharide is not an artifact, and that CHO cells are capable of producing a minor amount of endogenous 3-O-sulfation through an undetermined mechanism. Together, the analysis of the HS3STs indicates that they all have preferences for N-sulfated substrates, and that HS3ST5/2 have a strong preference for 2-O-sulfated substrates, while HS3ST3A/3B/4 have more promiscuous substrate specificity for N/2-O/6-O-sulfated substrates.

Divergent bioactivities of HS from HS3ST-expressing cells

To relate different 3-O-sulfated HS structures derived by the action of the HS3ST family to resulting bioactivities, and to also exploit this approach for initial development of a cell-based heparin with low PF4 binding (Fig. 1E), we tested our HS3ST library of CHO cells for anticoagulant activity and PF4 binding. We first performed flow cytometry assays probing ATIII binding to the HS3ST-expressing CHO cells where HS3ST1/5/3A/3B demonstrated similar binding, while HS3ST4 demonstrated the highest binding, HS3ST2 demonstrated low ATIII binding, and HS3ST6 demonstrated no binding




Fig. 4. Comprehensive analysis of HS from CHO cells expressing the human HS3ST family. (A) Genetic engineering strategy for dissecting effects of specific HS3ST isoenzyme expression in CHO cells. (B) HS extracted from CHO KO CS and *HS3ST4* KI cells was digested, and compositional disaccharide analysis was performed (a complete set of chromatograms can be found in fig. S12). Stars indicate heparinase enzyme peaks, and dotted lines indicate elution times for disaccharide standards. (C) Heat map analysis of the disaccharide products from the HS3ST-expressing cells. The heat map was constructed by quantifying the molar amounts of each disaccharide in a sample as percent of the total disaccharides and comparing this to the amounts found in the sample from the parental cell line. The color coding illustrates increase/decrease observed in percentile ranges as indicated: +++, >10% increase; ++, 5 to 10% increase; +, 1 to 5% increase; -, 1 to 5% decrease; ---, 5 to 10% decrease; ----, >10% decrease. (D) FXa assay determining the anticoagulant activity of HS from the genetically engineered cells and select clinical heparin/LMWHs. The y axis shows absorbance at 405 nm, which is indicative of the amount of substrate cleaved by FXa for different concentrations of heparins/HS. All experiments were performed with duplicates and repeated a minimum of three times. (E) Biolayer interferometry assay for determining PF4 binding. The y axis shows the PF4-binding signal (nanometer) at two doses (125 and 500 nM). All experiments were performed a minimum of two times.

(fig. S14). Treatment with heparinases abolished ATIII binding to all cells. Next, we analyzed the anticoagulant activity of HS isolated from the engineered CHO cells and compared these to clinical heparin/LMWHs using anti-FXa assays (Fig. 4D and fig. S15A). HS from CHO KO CS demonstrated no measurable anticoagulant activity, while CHO cell HS produced by HS3ST1 showed anticoagulant activity in agreement with previous studies (44), further providing support for the prediction that HS3ST1 functions intracellularly in the HS biosynthesis despite being primarily secreted. CHO cell HS from HS3ST5/4/3A/3B demonstrated even higher levels of activity than HS3ST1, while CHO cell HS from HS3ST2 had comparatively low levels and HS3ST6 demonstrated no anticoagulant activity. To enable comparison of anticoagulant activity between the cellular-derived HS and heparins, we calculated half maximal inhibitory concentration (IC₅₀) values from the FXa data, where lower IC₅₀ values indicate more potent activity (fig. S16). Remarkably, the FXa activities of some of the CHO cell-derived HS were comparable to the activities found for some of the LMWHs. Thus, HS produced by CHO cells with KI of *HS3ST4* exhibit almost 80% of the activity found for the LMWH reviparin. In clinical practice, the low IC₅₀ of heparin is not necessary to achieve the anticoagulant effect, as LMWHs are efficient in the treatment of thrombosis and are clinically more commonly used than heparin. Comparing the results of ATIII binding and FXa assays with disaccharide analysis, it emerged that the inability of HS3ST2/6 to produce ΔUA-GlcNS3S (D0S3) may have had an impact on their ability to produce anticoagulant structures, which was an unexpected finding. HS from CHO cells with KI of N-sulfation (CHO KI *NDST2*) and 6-O-sulfation (CHO KI *HS6ST1*) (30) did not demonstrate anticoagulant activity, emphasizing the importance of 3-O-sulfation over N-/6-O-sulfation.

HIT is a potential life-threatening, immune-mediated adverse drug reaction to heparin due to the formation of PF4-heparin complexes. For the generation of cell-based HS as an alternative to animal heparins, we thus explored the PF4 binding of HS from the *HS3ST1* to *HS3ST6* KI cell lines (Fig. 4E and fig. S15B). CHO cell HS from *HS3ST4*-expressing cells demonstrated particularly low PF4 binding, despite exhibiting the highest anticoagulant activity, meaning that this isoenzyme is a potential candidate to use for bioengineering heparin with reduced potential to cause HIT. CHO cell HS from *HS3ST5/3B* also demonstrated comparatively low binding to PF4, while CHO cell HS from *HS3ST1/2/3A/6* exhibited increased binding compared to CHO KO CS. HS from CHO cells with KI of *HS6ST1* showed the strongest PF4 binding of all cellular HS, indicating that not only N-/2-O-sulfation but also 6-O-sulfation could be important for PF4-heparin complex formation. These data demonstrate the ability of the cell-based strategy to both identify and optimize HS bioactivities associated with distinct biosynthetic enzyme combinations.

DISCUSSION

The integrated strategies described here, incorporating an HPLC method for comprehensive disaccharide analysis, address a long-standing challenge in analysis of 3-O-sulfation in both HS and heparin. A comprehensive panel of 20 HS disaccharide standards, including eight 3-O-sulfated structures derived from synthetic compounds, made it possible to determine compositional differences in 3-O-sulfated disaccharides in both clinical heparins and HS derived from engineered CHO cells. The data provide insights into distinct action

patterns of the seven human HS3ST isoenzymes. Our studies revealed that ΔUA-GlcNS3S (D0S3) is an important feature for anticoagulant activity, and 6-O-sulfation is important for PF4 binding. In addition, we identified that CHO cell HS from cells expressing *HS3ST4* may be the optimal choice for cellular production of a heparin-like HS with high anticoagulant activity and low PF4 binding. This is a notable finding that could permit alleviation of the side effects of HIT often experienced with current animal-sourced heparins (Fig. 1E).

Although the critical role of 3-O-sulfation for anticoagulant activity of heparin was discovered in the 1980s, the importance of studying 3-O-sulfation has more recently emerged in the context of a much wider range of biological processes (2). To date, over 400 heparin/HS-binding proteins have been identified (53), yet only a handful of 3-O-sulfated structures have been identified or characterized (54). The HS3ST family has been most thoroughly studied at an organism level in zebrafish, where *hs3st2* and *hs3st4* were found to regulate brain symmetry and neuron growth, *hs3st5* and *hs3st6* play roles in cilia length and movement, and *hs3st7* plays a role in cardiac contractile apparatus. In zebrafish, *hs3st2* and *hs3st3* generate the epitope for herpes simplex virus-1 (HSV-1) viral entry, and *hs3st2* drives the epitope for tau plaques observed in Alzheimer's disease (20). In mice, flies, rats, and worms, the importance of HS3STs in organ development and inflammatory processes is well documented (2). The strategy developed here now allows dissection of the structural features involved in 3-O-sulfated HS binding to proteins in these processes.

Heparin remains one of few pharmaceuticals still isolated from animal tissues without thorough structural characterization (4, 55). The new compositional analysis method described here, which includes all major 3-O-sulfate-containing disaccharides, will facilitate improved quality control of clinical heparins. It will make it possible to better understand their structure-activity profiles, as well as to tailor and develop new pharmaceutical applications of heparins. It was observed that LMWHs dalteparin and reviparin contain high levels of ΔUA-GlcNS3S6S (D0S9) and ΔUA2S-GlcNS3S (D2S3). In contrast, partial depolymerization and fractionation of PMH to generate enoxaparin and tinzaparin do not seem to affect disaccharide composition greatly, as disaccharide profiles are similar to those for parental PMH.

Production of heparin in mammalian cells is considered a potential alternative to current animal sources, and advances have been made through overexpression and directed KI of enzymes functioning in the HS biosynthetic pathway (56). CHO cells have historically been chosen for genetic engineering (57, 58), and there is a need for custom-designed heparins with better safety profiles, such as reduced HIT. CHO cells stably expressing individual HS3STs had distinct differences in the composition of 3-O-sulfated HS disaccharides (Fig. 4, B and C). The analysis of the HS3STs indicates that they all have preferences for N-sulfated substrates and that *HS3ST5/2* have a strong preference for 2-O-sulfated substrates, while *HS3ST3A/3B/4* have more promiscuous substrate specificity for N/2-O/6-O-sulfated substrates. To explore the functional differences among the seven HS3STs, we tested the hypothesis that the HS3STs differentially regulate anticoagulant activity and PF4 binding (Fig. 4, D and E). This was clearly the case, and for example, CHO cell HS produced in *HS3ST4* cells induced very strong anticoagulant activity and almost no PF4 binding, while CHO cell HS from *HS3ST1* cells, the isoenzyme most commonly implicated in biosynthesis of anticoagulant

heparin/HS (44, 57), induced relatively strong PF4 binding and only moderate anticoagulant activity. We found evidence that 6-O-sulfation can be important for PF4 binding because HS from CHO KI *HS6ST1* induced particularly strong binding. This may be relevant for interpretation of the PF4-binding results, as heparins contain high levels of N-/6-/2-O-sulfated disaccharides. Our results highlight the need to further dissect the functions of the sulfotransferase isoenzyme families, their spatiotemporal expression, and their interplay in producing distinct binding motifs. Nevertheless, the findings here constitute an important step toward genetic engineering designs of CHO cells for production of heparin.

The study also increases the understanding of 3-O-sulfated motifs that lack anticoagulant activity, which may be desirable in the development of tailor-made GAG-based therapeutics where anticoagulant effects are unwanted. This may include GAG designs with anti-inflammatory, antitumor, antioxidant, and antiviral properties (59). Furthermore, the library of *HS3ST* KI cells can be applied beyond dissection of binding to ATIII and PF4 for determining binding specificities for known 3-O-sulfate-binding proteins such as neuropilin-1, cyclophilin B, stabilin, receptor for advanced glycation endproducts (RAGE), fibroblast growth factor-7 (FGF-7), FGF-9, FGF receptor-1 (FGFR-1), and bone morphogenetic protein 2 and 4 (BMP-2/4) (17, 60).

In summary, we describe an integrated strategy to analyze and determine biological properties of 3-O-sulfated HS structures. Proof of concept was demonstrated for the application of *HS3ST*-expressing cells for studying structure-function relationships and for production of heparins in mammalian host cells. This facilitated the development of improved heparins with potential for lower incidence of side effects. In combination with emerging HS sequencing methods, these approaches show promise for advancing discovery and characterization of the distinct motifs that direct the many biological interactions and functions of HS.

MATERIALS AND METHODS

Chemical synthesis of 3-O-sulfated tetrasaccharides and production of 3-O-sulfated disaccharide standards

General procedure for chemical glycosylation

Disaccharide acceptor (1.0 equiv), donor (1.2 equiv), and activated molecular sieves (4 Å) in dichloromethane (DCM) (0.2 M) were placed under an atmosphere of argon, and the resulting suspension was stirred at room temperature for 0.5 hour. The mixture was cooled (−20°C), triflic acid (TfOH; 1.5 equiv) was added, and the resulting reaction mixture was stirred at −20°C for an additional 1 hour, after which it was quenched by the addition of pyridine. The mixture was filtered, the filtrate was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography using a gradient of hexanes and EtOAc (from 4:1 to 1:9, v/v) to give a pure tetrasaccharide.

General procedure for O-sulfation

SO₃.NEt₃ complex (12.5 equiv per OH) was added to a solution of the hydroxyl-containing tetrasaccharide in *N,N'*-dimethylformamide (0.5 ml for 0.025 mmol), and the reaction mixture was stirred at 60°C for 16 hours. The reaction was quenched by the addition of a premixed solution of Et₃N/MeOH [1:1 (v/v), 1.0 ml], and stirring was continued for another 0.5 hour. The mixture was concentrated in vacuo, and the resulting residue was purified by SEC over Sephadex LH-20 (GE healthcare) using MeOH/DCM (1:1, v/v) as eluent. The desired fractions were combined and concentrated in vacuo,

and the residue was passed through a column of Dowex 50 × 8 Na⁺ resin (1.5 × 5 cm) using MeOH/H₂O (9:1, v/v) as eluent.

General procedure for N-acetylation

Acetic anhydride (Ac₂O; 10.0 equiv per amine) was added to a stirring solution of amino sugar in a mixture of MeOH (1.0 ml for 2.0 mg) and Et₃N (20.0 equiv per amine) at 0°C. After 4 hours, another portion of Et₃N and Ac₂O was added. After stirring at 0°C for additional 4 hours, the reaction mixture was concentrated in vacuo, and the residue was passed through a column of Dowex 50 × 8 Na⁺ resin (0.6 × 5 cm) using H₂O/AcCN (1:1, v/v) as eluent. Appropriate fractions were concentrated in vacuo and further purified by reversed-phase column chromatography (RP-18 silica gel column, H₂O/AcCN, 9:1 to 1:1, v/v).

General procedure for N-sulfation

SO₃.Py complex (5.0 equiv per amine) was added to a stirring solution of amino sugar in a mixture of MeOH (1.0 ml for 0.006 mmol), Et₃N (0.3 ml), and aq. NaOH (0.1 M, 2.0 equiv) at 0°C. Additional portions of SO₃.Py complex were added after 1, 2, 4, and 8 hours. After stirring at 0°C for additional 8 hours, the reaction mixture was concentrated in vacuo and the residue was passed through a column of Dowex 50 × 8 Na⁺ resin (0.6 × 5 cm) using H₂O/AcCN (9:1, v/v) as eluent. Appropriate fractions were concentrated in vacuo and further purified by reversed-phase chromatography (RP-18 silica gel column, H₂O/AcCN, 9.5:0.5 to 1:1, v/v).

General procedure for global deprotection

Pd(OH)₂/C (10%, 1.5 times the weight of starting material) was added to a solution of tetrasaccharide in *t*BuOH/0.1 M aq. formic acid [1:1 (v/v), 1.0 ml for 1.0 mg]. The mixture was placed under an atmosphere of hydrogen, and after stirring for 16 hours, the mixture was filtered through a Polytetrafluoroethylene (PTFE) syringe filter and lyophilized. The residue was analyzed by nuclear magnetic resonance to confirm complete deprotection and identity of the tetrasaccharide. The compound was dissolved in sodium phosphate buffer (pH was adjusted to 3.5 with formic acid to avoid peeling reaction), aliquoted, and stored at −80°C.

Heparinase digestion

For enzymatic digestion of heparins, cellular HS, and synthetic tetrasaccharides with heparinases I, II, and III (IBEX Pharmaceuticals), a digestion buffer with a final concentration of 50 mM sodium acetate and 5 mM calcium acetate (pH 6.5) was used. Freshly resuspended lyophilized heparinase I was added first, heparinase III was added after 2 hours, and heparinase II was added 2 hours later, followed by incubation overnight at 37°C. A detailed description of reaction volumes, sample quantities, and enzyme doses used for all heparinase digestions is found in table S5.

Mass spectrometry

Disaccharide standards labeled with AMAC were subjected to offline MS analysis in an Orbitrap Fusion/Lumos MS (Thermo Fisher Scientific) and a Synapt G2-S modified with a drift tube Ion mobility spectrometry (IMS) cell. In the Orbitrap Fusion/Lumos MS (Thermo Fisher Scientific), an atmospheric pressure ionization heated electrospray ionization source (Thermo Fisher Scientific) was used, and the ion transfer tube was set at 275°C. Mass spectra were acquired in negative ion mode at a resolution of 120,000 [at mass/charge ratio (*m/z*) of 200] with a spray voltage of 3000 V. In the Synapt G2-S, the disaccharides were ionized using Pd/Pt-coated borosilicate capillaries fabricated in-house in negative mode at a capillary voltage of

800 V. MS/MS was performed on selected ions in the trap cell of the instrument at either 15- or 30-V collision voltage.

C18 HPLC disaccharide analysis of AMAC-labeled disaccharides

HS from CHO cells and pharmaceutical heparins were digested with heparinases I, II, and III, and disaccharide products were lyophilized. The disaccharides were then labeled with AMAC by resuspension in 10 μ l of 0.1 M AMAC in 3:17 (v/v) acetic acid/dimethyl sulfoxide followed by incubation at room temperature for 15 min, before addition of 10 μ l of 1 M NaCNBH₃ and incubation at 45°C for 3 hours. The reactions were lyophilized, and excess AMAC was removed by two rounds of resuspension in 500 μ l of acetone and pelleting by centrifugation at 20,000g for 20 min at 4°C. Samples were dissolved in 2% acetonitrile and analyzed on a Waters Acquity UPLC system equipped with a fluorescence detector with a BEH C18 column (2.1 \times 150 mm, 1.7 μ m; Waters) detecting the fluorescence signal at 525 nm. A standard mix of AMAC-labeled disaccharides (20 pmol of each) was analyzed immediately before samples. Commercially available disaccharide standards were purchased from Iduron and Sigma-Aldrich.

Size exclusion analysis of heparinase-digested PMH

For determining the enzyme concentration needed for complete digestion of heparin, PMH was digested with increasing concentrations of heparinases I, II, and III, and digested samples were purified using the Discovery BIO Wide Pore C5 HPLC Column (4.6 mm by 250 mm, 6- μ m bead size; Sigma-Aldrich). Water was used as eluent A, and the flow-through was collected and lyophilized. The lyophilized samples were resuspended in 200 μ l of 0.5 M ammonium bicarbonate and separated on a Superdex 30 (10 mm by 300 mm by 9 μ m; GE Healthcare) SEC column using 0.5 M ammonium bicarbonate with monitoring at 232 nm. Standards of hexasaccharides (dp6), tetrasaccharides (dp4), and disaccharides (dp2) with one to three sulfate groups were used for calibration.

Anti-FXa assay

Human plasma ATIII (1 μ M) (Sigma-Aldrich) in 50 mM tris-HCl, 175 mM NaCl, and 7.5 mM EDTA (pH 8.4) and bovine FXa (1 μ M) (Sigma-Aldrich) were both diluted 1:30 in 0.9% NaCl, and 8 mM FXa substrate (Sigma-Aldrich) was diluted 1:10 in 0.9% NaCl immediately before assay. ATIII (37.5 μ l) was added to each well of a 96-well plate before adding heparin/HS samples at a range of concentrations diluted to 12.5 μ l in 0.9% NaCl. Mixtures were incubated for 2 min at 37°C before addition of bovine FXa (37.5 μ l) followed by 1-min incubation at 37°C. The FXa substrate (37.5 μ l) was then added followed by incubation at 37°C for 10 min before 37.5 μ l of acetic acid was used to stop the enzymatic reaction. Absorbance was read at 405 nm using a Synergy LX plate reader (BioTek), and IC₅₀ values used for quantification of anticoagulant activity relative to PMH were determined with an online AAT Bioquest IC₅₀ calculator.

Biolayer interferometry

GAGs were biotinylated at their reducing end as described previously (61). Briefly, biolayer interferometry was carried out using streptavidin biosensors (ForteBio) hydrated for 10 min before use in the assay buffer [10 mM HEPES, 150 mM NaCl, 3 mM EDTA, and 0.05% Tween 20 (pH 7.4)]. Hydrated sensors were then submerged into wells of a black-walled 96-well plate containing 200 μ l of biotinylated GAGs

suspended at 2.5 μ g/ml in assay buffer until saturated. Saturation was confirmed with an additional GAG immobilization step, where no further GAG was immobilized. Sensors were then cleaned by submersion in wells containing 200 μ l of regeneration buffer [0.1 M glycine, 1 M NaCl, and 0.1% Tween (pH 9.5)] and equilibrated in assay buffer. GAG-coated sensors were submerged in wells containing 200 μ l of PF4 resuspended in assay buffer for 180 s (association) and then transferred to wells containing assay buffer alone (dissociation), and data were recorded throughout. Background binding to non-GAG-coated sensors and signal produced by buffer alone was recorded and subtracted from the GAG-coated sensor signal. The maximum signal recorded during each cycle was then used as a measure of the degree of binding of PF4 to each GAG at different concentrations. Between cycles, bound PF4 was removed from GAG-coated sensors using regeneration buffer and sensors were then equilibrated in assay buffer. Data were acquired using an Octet Red96 system (ForteBio) at 5 Hz and analyzed using the Octet analysis program.

Genetic engineering of CHO cells

CHOZN GS^{-/-} (Sigma-Aldrich) cells were maintained as suspension culture in T-flasks at 37°C and 5% CO₂ using a 1:1 mix of EXCELL CD CHO Fusion (Sigma-Aldrich) and BalanCD CHO Growth A (Irvine scientific), supplemented with 2 mM L-glutamine. For targeted KI at the CHO SafeHarbor locus, a modified ZFN ObLiGare method was used as previously described (58, 62). Full complementary DNAs of coding regions of the human *HS3STs* (Horizon Discovery and Harvard PlasmID Database) were used, a C-terminal S-tag or V5-tag was linked to *HS3STs* by polymerase chain reaction (PCR), and constructs were further cloned into the EPB69 donor plasmid. EPB69 contained inverted CHO SafeHarbor locus ZFN-binding sites flanking the cytomegalovirus promoter-ORF (open reading frame)-BGH (bovine growth hormone) polyA terminator and two tDNA insulator elements flanking the ZFN-binding sites, as previously described (58, 63). Transfection DNA mixes contained 4.5 μ g of donor plasmid DNA and 1.5 μ g of each of two ZFNs tagged with green fluorescent protein (GFP) and Crimson, respectively. For each transfection, 1.5×10^6 cells were electroporated using Amaxa Kit V and Amaxa Nucleofector 2B (Lonza) according to the manufacturer's instructions. Forty-eight hours after transfection, 10 to 15% of cells with the highest labeling for both GFP and Crimson were enriched by fluorescence-activated cell sorting (FACS) on SH800 (Sony). One week later, the FACS-sorted cell pool was further single cell-sorted into round-bottom 96-well plates with Dulbecco's Modified Eagle Medium F-12 Nutrient Mixture (Thermo Fisher Scientific) to obtain single clones. KI clones were screened by immunocytochemistry, and monoallelic-targeted KI clones were validated by PCR with primers specific for the junction area between the donor plasmid and the SafeHarbor locus. A primer set flanking the targeted KI locus was also used to characterize the allelic insertion status. A minimum of three clones were obtained for each *HS3ST* KI.

Immunocytochemistry

CHO cells were washed in phosphate-buffered saline (PBS), spotted onto Teflon printed diagnostic slides (Immuno-Cell International), air-dried, and permeabilized with ice-cold acetone for 5 min. Polyclonal antibodies to S-tag (GenScript) were used 1:200 in PBS with 0.1% bovine serum albumin (BSA) at 4°C overnight followed by fluorescein isothiocyanate (FITC)-conjugated rabbit anti-mouse

immunoglobulin G (IgG) antibody (DAKO) 1:300 in 1× PBS with 0.1% BSA for 1 hour at room temperature. An FITC-conjugated monoclonal antibody to V5-tag (Thermo Fisher Scientific) was used 1:500 in PBS with 0.1% BSA at 4°C overnight. Slides were analyzed in an Axioskop 2 Plus (Zeiss) microscope, and images were obtained using an AxioCam MRc (Zeiss) camera.

SDS-PAGE Western blot

Cells (1×10^6) were seeded in a T25 flask in 6-ml medium and grown for 72 hours, before washing the cells three times in PBS and adding 700 μ l of cold radioimmunoprecipitation assay (RIPA) buffer [50 mM tris-HCl (pH 7.5), 150 mM NaCl, 1% NP-40, 0.1% Na deoxycholate, and 1 mM EDTA] containing protease inhibitor cocktail (Sigma-Aldrich). Samples were thoroughly vortexed before incubation for 20 min on ice with vortexing every 5 min followed by ultrasonication (40% amplitude) for 3×5 s with 5-s pauses using the Fisherbrand Model 120 Sonic Dismembrator (Thermo Fisher Scientific). Samples were centrifuged at 20,000g at 4°C for 15 min, and the protein concentration of the supernatant was measured using a BCA protein assay kit (Thermo Fisher Scientific). Protein (10 μ g) or the corresponding fraction of medium used for culturing cells to obtain 10 μ g of protein was mixed with 10 mM DDT (Dichlorodiphenyltrichloroethane) and 1× loading buffer, heated to 90°C for 10 min, and separated on NuPAGE 4 to 12% Bis-Tris gels (Thermo Fisher Scientific). Proteins were transferred to nitrocellulose membranes at 320 mA for 60 min in MES buffer with 20% methanol. Membranes were blocked with 5% skimmed milk in TBS-T (tris-buffered saline tween-20) for 60 min before they were incubated with either horseradish peroxidase (HRP)-conjugated antibodies to V5-tag (Thermo Fisher Scientific) or S-tag in TBS-T with 5% skimmed milk at 4°C overnight. Membranes were washed 3×5 min in TBS-T followed by incubation of S-tag membranes with HRP-conjugated rabbit anti-mouse IgG antibody (DAKO) in 5% skimmed milk in TBS-T for 1 hour at room temperature and washing 3×5 min in TBS-T. Pierce ECL Plus Western Blotting Substrate (Thermo Fisher Scientific) was used according to the manufacturer's instructions, and images were captured using ImageQuant Las 4000 (GE Healthcare).

Extraction and purification of GAGs from CHO cells

Cells were washed in PBS and diluted to 1×10^7 cells/ml in 50 mM tris-HCl (pH 7.4), 10 mM CaCl₂, and 0.1% Triton X-100. Pronase (Roche) was added (1 mg/ml), and reactions were incubated overnight rotating tray in an incubator set at 37°C followed by heat inactivation. MgCl₂ (5 mM) and deoxyribonuclease I (1 μ g/ml; Sigma-Aldrich) were added, and samples were incubated at 37°C for 4 hours. Samples were treated with ribonuclease A (10 μ g/ml; Sigma-Aldrich) and 5 mM EDTA at 37°C for 2 hours, followed by neuraminidase (0.5 mU/ml; Sigma-Aldrich) at 37°C overnight. For cells expressing CS, chABC (chondroitinase ABC) (20 mU/ml) was added and samples were incubated at 37°C for 4 hours. Samples were again incubated with pronase at 1 mg/ml for overnight digestion at 37°C. Samples were acidified to pH 4 to 5 with acetic acid, centrifuged at 20,000g for 20 min, filtered through 0.45- μ m filters, and isolated on HiTrap DEAE FF columns (5 ml; GE Healthcare). Columns were equilibrated with 20 mM NaOAc and 0.5 M NaCl (pH 5.0), and samples were eluted with 1.25 M NaCl. GAGs were precipitated by addition of cold NaOAc-saturated 100% ethanol (3:1, v/v) and centrifuged at 20,000g for 20 min at 4°C, and

the pellets were dried on SpeedVac. Samples were resuspended in deionized water, further purified using Discovery BIO Wide Pore C5-5 (Sigma-Aldrich), and desalted on 1-ml HiTrap desalting columns (GE Healthcare).

Flow cytometry assays

Cells at 50 to 80% confluence were detached with PBS containing 10 mM EDTA (Gibco) and washed in PBS containing 0.5% BSA. The cells were seeded into a 96-well plate at 10^5 cells per well. A portion of the cells were treated with a heparinase mix [heparinase II (2.5 mU/ml) and heparinase III (5 mU/ml); IBEX] for 30 min at 37°C in PBS containing 0.5% BSA. Staining with recombinant ATIII (Hyphen BioMed) (500 nM) was done for 1 hour at 4°C in PBS containing 0.5% BSA. Cells were then incubated with an anti-ATIII antibody (Serp-C1, R&D Systems) for 30 min at 4°C in PBS containing 0.5% BSA. The bound complex was finally detected using anti-goat Alexa Fluor 488 (Thermo Fisher Scientific). Data analysis was performed using FlowJo software, and statistical analyses were done in Prism 8 (GraphPad).

SUPPLEMENTARY MATERIALS

Supplementary material for this article is available at <https://science.org/doi/10.1126/sciadv.abl6026>

[View/request a protocol for this paper from Bio-protocol.](#)

REFERENCES AND NOTES

1. D. Soares da Costa, R. L. Reis, I. Pashkuleva, Sulfation of glycosaminoglycans and its implications in human health and disorders. *Annu. Rev. Biomed. Eng.* **19**, 1–26 (2017).
2. D. Xu, J. D. Esko, Demystifying heparan sulfate-protein interactions. *Annu. Rev. Biochem.* **83**, 129–157 (2014).
3. C. A. Glass, Recombinant heparin—new opportunities. *Front. Med.* **5**, 341 (2018).
4. E. I. Oduah, R. J. Linhardt, S. T. Sharfstein, Heparin: Past, present, and future. *Pharmaceuticals (Basel)* **9**, 38 (2016).
5. G. Spadarella, A. di Minno, M. B. Donati, M. Mormile, I. Ventre, G. di Minno, From unfractionated heparin to pentasaccharide: Paradigm of rigorous science growing in the understanding of the in vivo thrombin generation. *Blood Rev.* **39**, 100613 (2020).
6. L. Fu, G. Li, B. Yang, A. Onishi, L. Li, P. Sun, F. Zhang, R. J. Linhardt, Structural characterization of pharmaceutical heparins prepared from different animal tissues. *J. Pharm. Sci.* **102**, 1447–1457 (2013).
7. H. Liu, Z. Zhang, R. J. Linhardt, Lessons learned from the contamination of heparin. *Nat. Prod. Rep.* **26**, 313–321 (2009).
8. E. Vilanova, A. M. F. Tovar, P. A. S. Mourao, Imminent risk of a global shortage of heparin caused by the African Swine Fever afflicting the Chinese pig herd. *J. Thromb. Haemost.* **17**, 254–256 (2019).
9. J. A. Huntington, Mechanisms of glycosaminoglycan activation of the serpins in hemostasis. *J. Thromb. Haemost.* **1**, 1535–1549 (2003).
10. Y. S. Kim, R. J. Linhardt, Structural features of heparin and their effect on heparin cofactor II mediated inhibition of thrombin. *Thromb. Res.* **53**, 55–71 (1989).
11. M. Petitou, P. Duchaussoy, J. M. Herbert, G. Duc, M. el Hajji, J. F. Branellec, F. Donat, J. Necciari, R. Cariou, J. Bouthier, E. Garrigou, The synthetic pentasaccharide fondaparinux: First in the class of antithrombotic agents that selectively inhibit coagulation factor Xa. *Semin. Thromb. Hemost.* **28**, 393–402 (2002).
12. D. H. Atha, J. C. Lormeau, M. Petitou, R. D. Rosenberg, J. Choay, Contribution of monosaccharide residues in heparin binding to antithrombin III. *Biochemistry* **24**, 6723–6729 (1985).
13. L. Rauova, M. Poncz, S. E. McKenzie, M. P. Reilly, G. Arepally, J. W. Weisel, C. Nagaswami, D. B. Cines, B. S. Sachais, Ultralarge complexes of PF4 and heparin are central to the pathogenesis of heparin-induced thrombocytopenia. *Blood* **105**, 131–138 (2005).
14. D. P. Dyer, C. L. Salanga, B. F. Volkman, T. Kawamura, T. M. Handel, The dependence of chemokine-glycosaminoglycan interactions on chemokine oligomerization. *Glycobiology* **26**, 312–326 (2016).
15. I. Ahmed, A. Majeed, R. Powell, Heparin induced thrombocytopenia: Diagnosis and management update. *Postgrad. Med. J.* **83**, 575–582 (2007).
16. S. E. Stringer, J. T. Gallagher, Specific binding of the chemokine platelet factor 4 to heparan sulfate. *J. Biol. Chem.* **272**, 20508–20514 (1997).

17. P. Chopra, A. Joshi, J. Wu, W. Lu, T. Yadavalli, M. A. Wolfert, D. Shukla, J. Zaia, G. J. Boons, The 3-O-sulfation of heparan sulfate modulates protein binding and lyase degradation. *Proc. Natl. Acad. Sci. U.S.A.* **118**, e2012935118 (2021).
18. V. M. Dhurandhare, V. Pagadala, A. Ferreira, L. Mlynck, J. Liu, Synthesis of 3-O-sulfated disaccharide and tetrasaccharide standards for compositional analysis of heparan sulfate. *Biochemistry* **59**, 3186–3192 (2020).
19. S. Yamada, K. Yoshida, M. Sugiura, K. Sugahara, K. H. Khoo, H. R. Morris, A. Dell, Structural studies on the bacterial lyase-resistant tetrasaccharides derived from the antithrombin III-binding site of porcine intestinal heparin. *J. Biol. Chem.* **268**, 4780–4787 (1993).
20. A. B. Cadwallader, H. J. Yost, Combinatorial expression patterns of heparan sulfate sulfotransferases in zebrafish: I. The 3-O-sulfotransferase family. *Dev. Dyn.* **235**, 3423–3431 (2006).
21. R. Lawrence, T. Yabe, S. Hajmohammadi, J. Rhodes, M. McNeely, J. Liu, E. D. Lamperti, P. A. Toselli, M. Lech, P. G. Spear, R. D. Rosenberg, N. W. Shworak, The principal neuronal gD-type 3-O-sulfotransferases and their products in central and peripheral nervous system tissues. *Matrix Biol.* **26**, 442–455 (2007).
22. B. E. Thacker, D. Xu, R. Lawrence, J. D. Esko, Heparan sulfate 3-O-sulfation: A rare modification in search of a function. *Matrix Biol.* **35**, 60–72 (2014).
23. J. Liu, N. W. Shworak, L. M. Fritze, J. M. Edelberg, R. D. Rosenberg, Purification of heparan sulfate D-glucosaminyl 3-O-sulfotransferase. *J. Biol. Chem.* **271**, 27072–27082 (1996).
24. G. Xia, J. Chen, V. Tiwari, W. Ju, J. P. Li, A. Malmström, D. Shukla, J. Liu, Heparan sulfate 3-O-sulfotransferase isoform 5 generates both an antithrombin-binding site and an entry receptor for herpes simplex virus, type 1. *J. Biol. Chem.* **277**, 37912–37919 (2002).
25. A. F. Moon, S. C. Edavettal, J. M. Krahn, E. M. Munoz, M. Negishi, R. J. Linhardt, J. Liu, L. C. Pedersen, Structural analysis of the sulfotransferase (3-O-sulfotransferase isoform 3) involved in the biosynthesis of an entry receptor for herpes simplex virus 1. *J. Biol. Chem.* **279**, 45185–45193 (2004).
26. S. Gulberti, X. Mao, C. Bui, S. Fournel-Gigleux, The role of heparan sulfate maturation in cancer: A focus on the 3O-sulfation and the enigmatic 3O-sulfotransferases (HS3ST5). *Semin. Cancer Biol.* **62**, 68–85 (2020).
27. C. Hellec, M. Delos, M. Carpentier, A. Denys, F. Allain, The heparan sulfate 3-O-sulfotransferases (HS3ST 2, 3B and 4 enhance proliferation and survival in breast cancer MDA-MB-231 cells. *PLoS ONE* **13**, e0194676 (2018).
28. J. E. Sepulveda-Diaz, S. M. Alavi Naini, M. B. Huynh, M. O. Ouidja, C. Yanicostas, S. Chantepie, J. Villares, F. Lamari, E. Jospin, T. H. van Kuppevelt, A. G. Mensah-Nyagan, R. Raisman-Vozari, N. Soussi-Yanicostas, D. Papy-Garcia, HS3ST2 expression is critical for the abnormal phosphorylation of tau in Alzheimer's disease-related tau pathology. *Brain* **138**, 1339–1354 (2015).
29. L. Kjellén, U. Lindahl, Specificity of glycosaminoglycan-protein interactions. *Curr. Opin. Struct. Biol.* **50**, 101–108 (2018).
30. Y. H. Chen, Y. Narimatsu, T. M. Clausen, C. Gomes, R. Karlsson, C. Steentoft, C. B. Spliid, T. Gustavsson, A. Salanti, A. Persson, A. Malmström, D. Willén, U. Ellervik, E. P. Bennett, Y. Mao, H. Clausen, Z. Yang, The GAGome: A cell-based library of displayed glycosaminoglycans. *Nat. Methods* **15**, 881–888 (2018).
31. H. Qiu, S. Shi, J. Yue, M. Xin, A. V. Nairn, L. Lin, X. Liu, G. Li, S. A. Archer-Hartmann, M. dela Rosa, M. Galizzi, S. Wang, F. Zhang, P. Azadi, T. H. van Kuppevelt, W. V. Cardoso, K. Kimata, X. Ai, K. W. Moremen, J. D. Esko, R. J. Linhardt, L. Wang, A mutant-cell library for systematic analysis of heparan sulfate structure-function relationships. *Nat. Methods* **15**, 889–899 (2018).
32. C. Zong, A. Venot, X. Li, W. Lu, W. Xiao, J. S. L. Wilkes, C. L. Salanga, T. M. Handel, L. Wang, M. A. Wolfert, G. J. Boons, Heparan sulfate microarray reveals that heparan sulfate-protein binding exhibits different ligand requirements. *J. Am. Chem. Soc.* **139**, 9534–9543 (2017).
33. R. L. Miller, S. E. Guimond, R. Schwörer, O. V. Zubkova, P. C. Tyler, Y. Xu, J. Liu, P. Chopra, G. J. Boons, M. Grabarics, C. Manz, J. Hofmann, N. G. Karlsson, J. E. Turnbull, W. B. Struwe, K. Pagel, Shotgun ion mobility mass spectrometry sequencing of heparan sulfate saccharides. *Nat. Commun.* **11**, 1481 (2020).
34. R. L. Miller, A. B. Dykstra, W. Wei, C. Holsclaw, J. E. Turnbull, J. A. Leary, Enrichment of two isomeric heparin oligosaccharides exhibiting different affinities toward monocyte chemoattractant protein-1. *Anal. Chem.* **88**, 11551–11558 (2016).
35. M. Lettow, M. Grabarics, K. Greis, E. Mucha, D. A. Thomas, P. Chopra, G. J. Boons, R. Karlsson, J. E. Turnbull, G. Meijer, R. L. Miller, G. von Helden, K. Pagel, Cryogenic infrared spectroscopy reveals structural modularity in the vibrational fingerprints of heparan sulfate diastereomers. *Anal. Chem.* **92**, 10228–10232 (2020).
36. J. A. Leary, R. L. Miller, W. Wei, R. Schwörer, O. V. Zubkova, P. C. Tyler, J. E. Turnbull, Composition, sequencing and ion mobility mass spectrometry of heparan sulfate-like octasaccharide isomers differing in glucuronic and iduronic acid content. *Eur. J. Mass Spectrom.* **21**, 245–254 (2015).
37. J. Wu, J. Wei, P. Chopra, G. J. Boons, C. Lin, J. Zaia, Sequencing heparan sulfate using HILIC LC-NETD-MS/MS. *Anal. Chem.* **91**, 11738–11746 (2019).
38. Q. Liang, P. Chopra, G. J. Boons, J. S. Sharp, Improved de novo sequencing of heparin/heparan sulfate oligosaccharides by propionylation of sites of sulfation. *Carbohydr. Res.* **465**, 16–21 (2018).
39. Y. Xu, S. Masuko, M. Takeddin, H. Xu, R. Liu, J. Jing, S. A. Mousa, R. J. Linhardt, J. Liu, Chemoenzymatic synthesis of homogeneous ultralow molecular weight heparins. *Science* **334**, 498–501 (2011).
40. D. L. Lohse, R. J. Linhardt, Purification and characterization of heparin lyases from *Flavobacterium heparinum*. *J. Biol. Chem.* **267**, 24347–24355 (1992).
41. Y. Huang, Y. Mao, C. Zong, C. Lin, G. J. Boons, J. Zaia, Discovery of a heparan sulfate 3-O-sulfation specific peeling reaction. *Anal. Chem.* **87**, 592–600 (2015).
42. S. N. Baytas, R. J. Linhardt, Advances in the preparation and synthesis of heparin and related products. *Drug Discov. Today* **25**, 2095–2109 (2020).
43. G. J. Merli, J. B. Groce, Pharmacological and clinical differences between low-molecular-weight heparins: Implications for prescribing practice and therapeutic interchange. *PT* **35**, 95–105 (2010).
44. P. Datta, G. Li, B. Yang, X. Zhao, J. Y. Baik, T. R. Gemmill, S. T. Sharfstein, R. J. Linhardt, Bioengineered Chinese hamster ovary cells with Golgi-targeted 3-O-sulfotransferase-1 biosynthesize heparan sulfate with an antithrombin-binding site. *J. Biol. Chem.* **288**, 37308–37318 (2013).
45. L. Zhang, R. Lawrence, B. A. Frazier, J. D. Esko, CHO glycosylation mutants: Proteoglycans. *Methods Enzymol.* **416**, 205–221 (2006).
46. X. Xu, H. Nagarajan, N. E. Lewis, S. Pan, Z. Cai, X. Liu, W. Chen, M. Xie, W. Wang, S. Hammond, M. R. Andersen, N. Neff, B. Passarelli, W. Koh, H. C. Fan, J. Wang, Y. Gui, K. H. Lee, M. J. Betenbaugh, S. R. Quake, I. Famili, B. O. Palsson, J. Wang, The genomic sequence of the Chinese hamster ovary (CHO)-K1 cell line. *Nat. Biotechnol.* **29**, 735–741 (2011).
47. S. K. Cho, R. D. Cummings, A soluble form of α 1,3-Galactosyltransferase functions within cells to galactosylate glycoproteins. *J. Biol. Chem.* **272**, 13622–13628 (1997).
48. G. Zhu, M. L. Allende, E. Jaskiewicz, R. Qian, D. S. Darling, C. A. Worth, K. J. Colley, W. W. Young, Two soluble glycosyltransferases glycosylate less efficiently in vivo than their membrane bound counterparts. *Glycobiology* **8**, 831–840 (1998).
49. P. H. Kuhn, M. Voss, M. Haug-Kröper, B. Schröder, U. Schepers, S. Bräse, C. Haass, S. F. Lichtenthaler, R. Fluhrer, Secretome analysis identifies novel signal peptide peptidase-like 3 (Sppl3) substrates and reveals a role of Sppl3 in multiple Golgi glycosylation pathways. *Mol. Cell. Proteomics* **14**, 1584–1598 (2015).
50. H. Habuchi, O. Habuchi, K. Kimata, Purification and characterization of heparan sulfate 6-sulfotransferase from the culture medium of Chinese hamster ovary cells. *J. Biol. Chem.* **270**, 4172–4179 (1995).
51. J. Chen, J. Liu, Characterization of the structure of antithrombin-binding heparan sulfate generated by heparan sulfate 3-O-sulfotransferase 5. *Biochim. Biophys. Acta* **1725**, 190–200 (2005).
52. H. Mochizuki, K. Yoshida, M. Gotoh, S. Sugioka, N. Kikuchi, Y. D. Kwon, A. Tawada, K. Maeyama, N. Inaba, T. Hiruma, K. Kimata, H. Narimatsu, Characterization of a heparan sulfate 3-O-sulfotransferase-5, an enzyme synthesizing a tetrasulfated disaccharide. *J. Biol. Chem.* **278**, 26780–26787 (2003).
53. A. Ori, M. C. Wilkinson, D. G. Fernig, A systems biology approach for the investigation of the heparin/heparan sulfate interactome. *J. Biol. Chem.* **286**, 19892–19904 (2011).
54. J. K. Meissen, M. D. Sweeney, M. Girardi, R. Lawrence, J. D. Esko, J. A. Leary, Differentiation of 3-O-sulfated heparin disaccharide isomers: Identification of structural aspects of the heparin CCL2 binding motif. *J. Am. Soc. Mass Spectrom.* **20**, 652–657 (2009).
55. D. Vaidyanathan, A. Williams, J. S. Dordick, M. A. G. Koffas, R. J. Linhardt, Engineered heparins as new anticoagulant drugs. *Bioeng. Transl. Med.* **2**, 17–30 (2017).
56. M. S. Lord, B. Cheng, F. Tang, J. G. Lyons, J. Rnjak-Kovacina, J. M. Whitelock, Bioengineered human heparin with anticoagulant activity. *Metab. Eng.* **38**, 105–114 (2016).
57. J. Y. Baik, L. Gasimli, B. Yang, P. Datta, F. Zhang, C. A. Glass, J. D. Esko, R. J. Linhardt, S. T. Sharfstein, Metabolic engineering of Chinese hamster ovary cells: Towards a bioengineered heparin. *Metab. Eng.* **14**, 81–90 (2012).
58. Z. Yang, S. Wang, A. Halim, M. A. Schulz, M. Frodin, S. H. Rahman, M. B. Vester-Christensen, C. Behrens, C. Kristensen, S. Y. Vakhrushev, E. P. Bennett, H. H. Wandall, H. Clausen, Engineered CHO cells for production of diverse, homogeneous glycoproteins. *Nat. Biotechnol.* **33**, 842–844 (2015).
59. M. Qiu, S. Huang, C. Luo, Z. Wu, B. Liang, H. Huang, Z. Ci, D. Zhang, L. Han, J. Lin, Pharmacological and clinical application of heparin progress: An essential drug for modern medicine. *Biomed. Pharmacother.* **139**, 111561 (2021).
60. B. E. Thacker, E. Seamen, R. Lawrence, M. W. Parker, Y. Xu, J. Liu, C. W. Vander Kooi, J. D. Esko, Expanding the 3-O-sulfate proteome—Enhanced binding of neuropilin-1 to 3-O-sulfated heparan sulfate modulates its activity. *ACS Chem. Biol.* **11**, 971–980 (2016).
61. D. Thakar, E. Migliorini, L. Coche-Guerente, R. Sadir, H. Lortat-Jacob, D. Boturyn, O. Renaudet, P. Labbe, R. P. Richter, A quartz crystal microbalance method to study the terminal functionalization of glycosaminoglycans. *Chem. Commun. (Camb.)* **50**, 15148–15151 (2014).

62. M. Maresca, V. G. Lin, N. Guo, Y. Yang, Obligate ligation-gated recombination (ObLiGaRe): Custom-designed nuclease-mediated targeted integration through nonhomologous end joining. *Genome Res.* **23**, 539–546 (2013).
63. J. Hintze, Z. Ye, Y. Narimatsu, T. D. Madsen, H. J. Joshi, C. K. Goth, A. Linstedt, C. Bachert, U. Mandel, E. P. Bennett, S. Y. Vakhrushev, K. T. Schjoldager, Probing the contribution of individual polypeptide GalNAc-transferase isoforms to the O-glycoproteome by inducible expression in isogenic cell lines. *J. Biol. Chem.* **293**, 19064–19077 (2018).
64. B. Domon, C. E. Costello, A systematic nomenclature for carbohydrate fragmentations in FAB-MS/MS spectra of glycoconjugates. *Glycoconj. J.* **5**, 397–409 (1988).
65. S. Arungundram, K. al-Mafraji, J. Asong, F. E. Leach III, I. J. Amster, A. Venot, J. E. Turnbull, G. J. Boons, Modular synthesis of heparan sulfate oligosaccharides for structure-activity relationship studies. *J. Am. Chem. Soc.* **131**, 17394–17405 (2009).

Acknowledgments: We thank H. Birchenough and the Biomolecular analysis core facility at the University of Manchester for help in establishing the chemokine:GAG interaction methodology. We also thank E. Yates, M. Skidmore, and S. Guimond for supplying four commercially available heparins. **Funding:** This work was funded by The Carlsberg Foundation CF20-0412 (R.L.M.); The Lundbeck Foundation, R223-2016-563 (H.C.); The Danish National Research Foundation DNR107 (H.C.); The European Commission, Glycolmaging H2020-MSCA-ITN-721297 (H.C. and R.K.); NIH, P41GM103390 and HLBI R01HL151617 (G.-J.B.);

The Sir Henry Dale Fellowship, Wellcome Trust/Royal Society 218570/Z/19/Z (D.P.D.); The National Science Foundation, RAPID 2031989 (J.E.T.); NIH, HL131474 (J.D.E.); and The Deutsche Forschungsgemeinschaft, German Research Foundation SFB 1340 (K.P.). **Author contributions:** Conceptualization: R.K., P.C., Z.Y., J.E.T., H.C., G.-J.B., and R.L.M. Methodology: R.K., P.C., A.J., Z.Y., S.Y.V., T.M.C., C.D.P., G.P.S., Y.-H.C., D.R.S., L.H., J.D.E., K.P., D.P.D., and R.L.M. Investigation: R.K., P.C., A.J., Z.Y., S.Y.V., T.M.C., C.D.P., G.P.S., Y.-H.C., D.R.S., L.H., J.D.E., K.P., D.P.D., and R.L.M. Funding acquisition: H.C., G.-J.B., and R.L.M. Project administration: H.C., G.-J.B., and R.L.M. Supervision: H.C., G.-J.B., and R.L.M. Writing (original draft): R.K., P.C., Z.Y., J.E.T., H.C., G.-J.B., and R.L.M. Writing (review and editing): R.K., P.C., A.J., Z.Y., S.Y.V., T.M.C., C.D.P., G.P.S., Y.-H.C., D.R.S., L.H., J.D.E., K.P., D.P.D., J.E.T., H.C., G.-J.B., and R.L.M. **Competing interests:** Y.-H.C. is an employee of GlycoDisplay Aps, and Z.Y. and H.C. are cofounders of GlycoDisplay Aps and hold ownerships and financial interest in the company. The other authors declare no competing interests. **Data and materials availability:** All data needed to evaluate the conclusions in the paper are present in the paper and/or the Supplementary Materials. All cell lines are available on request under a standard material transfer agreement with University of Copenhagen for academic research purposes.

Submitted 24 July 2021

Accepted 8 November 2021

Published 22 December 2021

10.1126/sciadv.abl6026

Dissecting structure-function of 3-O-sulfated heparin and engineered heparan sulfates

Richard KarlssonPradeep ChopraApoorva JoshiZhang YangSergey Y. VakhrushevThomas Mandel ClausenChelsea D. PainterGergo P. SzekeresYen-Hsi ChenDaniel R. SandovalLars HansenJeffrey D. EskoKevin PagelDouglas P. DyerJeremy E. TurnbullHenrik ClausenGeert-Jan BoonsRebecca L. Miller

Sci. Adv., 7 (52), eabl6026. • DOI: 10.1126/sciadv.abl6026

View the article online

<https://www.science.org/doi/10.1126/sciadv.abl6026>

Permissions

<https://www.science.org/help/reprints-and-permissions>

Use of think article is subject to the [Terms of service](#)

Science Advances (ISSN) is published by the American Association for the Advancement of Science. 1200 New York Avenue NW, Washington, DC 20005. The title *Science Advances* is a registered trademark of AAAS.

Copyright © 2021 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution NonCommercial License 4.0 (CC BY-NC).